Clinical features of 19 patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia  

作　　者：王丽君 WANG Lijun(1st Affil Hosp,Soochow Univ,Jiangsu Instit Hematol,Natl Clin Med Res Center,Hematol Dis,Suzhou 215006)

机构地区：[1]1st Affil Hosp,Soochow Univ,Jiangsu Instit Hematol,Natl Clin Med Res Center,Hematol Dis,Suzhou 215006

出　　处：《China Medical Abstracts(Internal Medicine)》2023年第2期120-120,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To assess the clinical characteristics and prognosis of patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia(T-ALL).Methods The clinical data of 19 SIL-TAL1-positive T-ALL patients admitted to the First Affiliated Hospital of Soochow University between January 2014 and February 2022 were retrospectively computed and contrasted with SIL-TAL1-negative T-ALL patients.Results The median age of the19 SIL-TAL1-positive T-ALL patients was 15(7 to41 years),including 16 males(84.2%).SIL-TAL1-positive T-ALL patients had younger age,higher WBC,and hemoglobin compared with SIL-TAL1-negative TALL patients.There was no discrepancy in gender distribution,PLT,chromosome abnormality distribution,immunophenotyping,and complete remission(CR)rate.The 3-year overall survival(OS) was 60.9% and74.4%,respectively(HR=2.070,P=0.071).The3-year relapse-free survival(RFS) was 49.2% and70.6%,respectively(HR=2.275,P=0.040).

关 键 词：PATIENTS admitted LYMPHOBLASTIC 

分 类 号：R733.71[医药卫生—肿瘤]